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Background: To evaluate whether the addition of a probiotic could improve Helicobacter pylori (H.P.) eradication
rates and reduce the side effects of treatment in children.
Methods: Between July 2008 and July 2011 all patients with a clinical, laboratory and endoscopic diagnosis of H.P.
positive gastritis referred to our Unit were included in the study. Patients suffering from allergy to any of drugs
used in the study, with previous attempts to eradicate H.P. and those who received antibiotics, PPIs or probiotics
within 4 weeks were excluded from the present study. Patients were randomized into two therapy regimens
(group A and B): both groups received standard triple treatment (omeprazole, amoxicillin and clarithromycin) while
only group B patients were also given a probiotic (Probinul - Cadigroup). Patients compliance was evaluated at the
end of the treatment. Successful eradication was defined as a negative 13 C-urea breath test (C13-ubt) result four
weeks after therapy discontinuation.
Results: A total of 68 histopathologically proven H.P.-infection children (32 male and 36 females) were included in
the study. All of the patients in both groups used more than 90% of the therapies and no patients were lost at
follow up. All side effects were selflimiting and disappeared once the therapy was terminated. Epigastric pain was
observed in 6 (17.6%) group A vs 2 (5.8%) group B patients (P<0.05), nausea in 3 (8.8%) group A vs 1 (2.9%) group B
patients (P<0.05); vomiting and diarrhea were observed in 2(5.8%) and 8 (23.5%) group A patients, respectively and
never in group B (P<0.05). There was no significant difference between the two groups in terms of constipation
(5.8% in group A and B). Four weeks after the completion of therapy, 56/68 patients (82.3%) tested negative for H.P.
on C13-ubt. H.P. was eradicated in 26 patients (76.4%) in group A and in 30 patients (88.2%) in group B. There was
no significantly difference in the rate of H.P. eradication between group A and group B (p=0.1), although the
success rate for H.P. eradication was higher in group B than in group A.
Conclusion: The addition of a probiotic formula to triple therapy significantly decreased the frequency of epigastric
pain, nausea, vomiting and diarrhea.
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Helicobacter pylori (H.P.) infection is a major cause of
chronic gastritis and peptic ulcers and it is a risk factor
for gastric malignancies, adenocarcinoma and low grade
gastric mucosa associated lymphoid tissue (MALT) lym-
phoma [1]. According to the Maastricht III consensus re-
port, H.P. eradication is recommended for patients with
gastroduodenal ulcer disease, atrophic gastritis, MALT
lymphoma, first degree relatives of patients with gastric
cancer, patients with unexplained iron deficiency anemia
and chronic idiopathic thrombocytopenic purpura.
In both developed and developing countries, H.P. in-
fection is most frequently acquired during childhood,
and it is associated with family size, familial clustering,
low socioeconomic status and education. The first line
treatment for H.P. infection, as recommended by the
Maastricht 2–2000 Consensus Report , is a 7–14 days
triple therapy which includes amoxicilline, clarithromycin,
OR metronidazole and a proton-pump inhibitor (PPI) [2],
though new strategies may be required for treatment both
in adults and children. As for adults, “infanti” treatment
will fail in approximately 10-35% of patients, and H.P. in-
fection will remain resulting from several factors, includ-
ing nonadherence to therapy related to adverse effects or
complicated dosing regimens and increasing antibiotic re-
sistance [3-5]. To overcome this problem, both in adults
than in children, alternative and adjuvant therapies have
been added to conventional treatment, such as probiotics
(PB) [6,7]. Although there is some controversy as to
whether supplementation with probiotic improves the
H.P. eradication rates [8-10], several meta-analysis and re-
views have suggested that probiotics can improve the H.P.
eradication rate by approximately 5-10% [10-13]. How-
ever, it is evident that not all probiotics are created equal,
that the beneficial effects are strain specific, and each
strain must be evaluated individually. Besides treatment
studies on children are limited by the small number of
infected children in each individual center [14-16], there-
fore this study aimed to evaluate whether the addition of a
commercially multi-strain probiotics to a 7 days triple
therapy in children could improve H.P. eradication rates
and reduce the side effects of treatment.
Methods
Between July 2008 and July 2011 children referred to the
Department of Pediatrics of the University of Naples
with dyspeptic complaints such as heartburn, dyspepsia,
nausea and epigastric pain, were enrolled in this study.
The study was approved by Ethical Committee of the
University of Naples.
Pediatric patients with a clinical, laboratory and endo-
scopic diagnosis of H.P. positive gastritis and the other
conditions necessary H.P. eradication for Maastricht III
consensus report were included in the study. Exclusioncriteria were: 1) allergy to any of drugs used in the study 2)
previous attempts to eradicate H.P. 3) receipt of antibio-
tics, PPIs or probiotics within 4 weeks of the study. In-
formed consent was obtained from all patients and all
positive 13 C-urea breath test (C13-ubt) patients under-
went upper endoscopy.
Two samples were taken from the gastric antrum and
compass for histologic assessment, and the biopsy spe-
cimens were fixed in 10% formalin solution. Prepara-
tion were stained with hematoxylin-eosin and modified
Giemsa stains and were evaluated according to updated
Sydney classification.
H.P. positive patients were randomized into two the-
rapy regimens: patients in group A were given omepra-
zole (1 mg/kg before breakfast), amoxicillin (50 mg/kg
b.i.d. after meals), clarithromycin (15 mg/kg b.i.d. after
meals) for 7 days, whereas patients in group B were given
the same drugs and a probiotic once a day for 7 days.
Patients were instructed to take PPI 30 mins before
breakfast, the antibiotics 5 mins after breakfast and dinner,
and PB supplement in the afternoon. The PB supplement
was taken in a commercially available form containing 5 ×
109 Lactobacillus plantarum, 2 × 109 L. reuterii, 2 × 109 L.
casei subsp. rhamnosus, 2 × 109 Bifidobacterium infantis
and B. longum, 1 × 109 L. salivarius, 1 × 109 L. acidophi-
lus, 5 × 109 Streptococcus termophilus, and 1 × 109 L.
sporogenes (Lactobacillaceae). This PB formula (5g/dayose
q.d.) (Probinul - Cadigroup) was selected because it con-
tains high concentrations of a wide range of bacteria, as
well as inuline as a prebiotic.
Parents were asked to report any side effects of therapy
during the treatment period and were given a possible side
effect list, such as epigastric pain, nausea, diarrhea and
constipation. Patients compliance was evaluated at the
end of the treatment on the basis of diary that patients
were asked to fill with pill count and was considered as
completed if >90% of the medication had been taken.
Successful eradication was defined as a negative C13-
ubt result four weeks after discontinuation of the therapy.
Statistical analysis
Data were collected prospectically in an electronic data-
base (Excell Microsoft). Fisher’s exact test was carried out
to determine the efficacy of the two treatments. Results
were considered statistically significant for P values less
than 0.05.
Results
A total of 68 histopathologically proven H.P.-infection
children (32 male and 36 females) were included in the
study. The mean age of all children was 8,3 +/− 3,4 years.
The patients were randomized into group A (triple
therapy n 34 patients) and group B (triple therapy plus
probiotic n 34 patients) for H.P. eradication. The age
Table 1 Incidence of side effects of the treatment
Side Effects Group A (N=34) Group B (N=34) P value
Epigastric pain 6 (17.6%) 2 (5.8%) <0.05
Nausea 3 (8.8%) 1 (2.9%) <0.05
Vomiting 2 (5.8%) 0 <0.05
Diarrhea 8 (23.5%) 0 <0.05
Constipation 2 (5.8%) 2 (5.8%) N.S.
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group B were similar.
All of parents returned the daily diary filled up with
side-effects and pill count.
All of the patients in both groups used more than 90%
of the therapies and no patients were lost at follow up.
The prevalence of epigastric pain, nausea, vomiting and
diarrhea was significantly higher (P<0.05) in group A
than in group B . There was no significant difference bet-
ween the two groups in terms of constipation. (Detailed
data on side effects are summarized in Table 1).
All side effects were self-limiting and disappeared once
the therapy was terminated.
Four weeks after the completion of therapy, 56/68
patients (82.3%) tested negative for H.P. on C13-ubt. H.
P. was eradicated in 26 patients (76.4%) in group A and
in 30 patients (88.2%) in group B (Figure 1). There was
no significantly difference in the rate of H.P. eradication
between group A and group B (p=0,1), although the suc-
cess rate for H.P. eradication was higher in group B than
in group A.
Discussion
It is well known that childhood is an important period
for acquisition of H.P. infection. Intrafamiliar trasmis-
sion of the infection , especially from mother to child,
has been hypothisized as the major mode of dissemina-
tion [17]. H.P. is considered to be the major cause of
chronic gastritis and duodenal ulcer in childhood and an
important cofactor in the development of gastric cancerFigure 1 Patients enrollment and therapy flowchart.[18]. Unfortunately eradication therapy is not always
successful and reports of failed H.P. eradication therapy
are increasing. Therefore, recent review studies report
eradication rates of standard triple therapy in children
below 75% [14,19]. Moreover this regimens have the dis-
advantage of risking poor compliance and causing side-
effects especially in children. Nowadays there is consi-
derable interest in alternative therapies or adjunctive
treatment against H.P. to reduce some of the drawbacks
associated with the antibiotic consumption and to in-
crease the eradication rates. Some adjuvant therapy trials
both in adults and in children incorporate probiotics
[20-22].
In our study H.P. eradication was achieved in 82.3% of
patients. A little increase in the eradication rate and a
significant reduction in side effects were observed in
the group treated with triple therapy plus Probinul PB.
Resistant patients were offered to second line therapy
(omeprazole 1 mg/kg/d, amoxicillin 50 mg/kg/d and
metronidazole 20 mg/kg/d), according to NASPGHAN
guidelines, confirming the contribution of a high back-
ground resistance to clarithromycin. Also, guidelines on
HP infection in children issued so far suggest that the
antibiotic susceptibility test should be performed when-
ever available [15]. However, we did not performed sus-
ceptibility test for first line antibiotic therapy.
Probiotics include viable microorganism that have a
beneficial effects for the prevention and treatment of spe-
cific pathological conditions [23]. Principle mechanisms
include interference with pathogenic toxins, preservation
of cellular physiology , interference with pathogen attach-
ment and interaction with normal microbiota [24,25] .
In addition, stimulation or modulation of immune res-
ponses, both within the lumen and systemically, although
not clearly linked to H.P. infection, may contribute
[26,27]. Besides probiotics may be beneficial in reducing
adverse effects and increasing tolerability of HP eradica-
tion regimens. Several studies evaluated whether probiotic
supplementation might help to prevent or reduce drug-
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adults [28-30]. Up to date, in the pediatric population, few
randomized studies have evaluated whether consumption
of probiotics could increase H.P. eradication rates and re-
duce the side effects of treatment [31-33]. In fact, in a re-
cent trial by Szajewska et al. [33] was identified that the
use of Lactobacillus GG along with standard triple therapy
didn’t resulted in an increased eradication rate and de-
creased overall therapy-related side effects.
Some of these trials do not provide evidence on the
beneficial effect in children of supplementation of pro-
biotics to triple therapy for eradicating H.P. infection
nor for positively affecting therapy related symptoms
and overall treatment tolerance [34].
However other investigators have shown that in symp-
tomatic H.P. positive children, the occurrence of anti-
biotic associated side-effects was significantly reduced by
the addition of probiotics compared with the placebo
supplemented group [31].
H.P. eradication depends on a number of factor, in-
cluding patients compliance, adverse effects, bacterial re-
sistance, poor drug distribution and concentration, socio-
economic conditions and geographic differences. So anti-
biotic related side effects may be depending on diffe-
rent probiotic strains taken during the H.P. eradication
therapy.
In our study the choice of the Probinul probiotic for-
mula was determinated by the fact that it contains high
concentration of a wide range of bacteria, as well as inu-
line as prebiotic. Previously we have demonstrated that
this probiotic formula was able to reduce antibiotic
gastro-intestinal related side effects in children treated
with amoxicillin therapy for pneumonia infections [35].
Besides De Bortoli et al. have demonstrated that the
addition of bovine lactoferrin and this probiotic formula
to standard triple eradication therapy could improve the
H.P. eradication rate and reduce side effects in adult [36].
In this study the combination of standard triple the-
rapy + probiotic + bovine lactoferrin was more effective
than triple therapy alone. This could be explained by the
combined effect of the bactericidal and bacteriostatic
properties of bovine lactoferrin and the mechanism of
the probiotics including their direct, nonspecific, bacte-
riostatic activity and their enhancement of immunoglo-
bulin A production [37].
Probiotics may act through both immunological as well
as non-immunological mechanism in H.P. eradication.
The latest mechanism includes providing antimicrobial
substances, competing with H.P. for adhesion and pro-
viding a mucosal barrier. When there are decreases in
side effects, compliance improves [26]. The efficacy of
probiotic supplementation for reducing side effects during
the course of anti HP regimens appears to be dependent
of which probiotic species are used. In fact probioticsmust be metabolically active in the intestinal lumen, where
they should survive but not persist after the therapy regi-
men has been completed. They must be acid and bile re-
sistant and should be antagonist to pathogenic bacteria
[38-40].
The present study has shown that the addiction of the
Probinul probiotic formula to standard antibiotic treat-
ment reduced in children H.P. therapy-associated side
effects (occurrence of side effects: 61.5% in group A vs
14.5% in group B). The H.P. eradication was achieved in
26 of 34 patients in group A (76.4%) and in 30 of 34
patients (88.2%) in group B. Although the success rate
was higher in group A than in group B, the different was
not significant. Also, we preferred to use the conven-
tional 7-days triple therapy to better highlight the effi-
cacy of probiotic supplement; furthermore extending the
duration of therapy form 7 to 14 days is not clearly asso-
ciated with an increased eradication rate [41]. However,
our study presents some limitations, as a relative small
number of patients and absence of a placebo-control
group for the probiotics; also, the treatment group with
probiotics is likely to be superior to the control group if
the sample size is larger.
In conclusion our study suggests that the addition of
this probiotic formula to triple therapy did not increase
(significantly) the H.P. eradication rates; however it sig-
nificantly decreased the frequency of epigastric pain,
nausea, vomiting and diarrhea.
In children with H.P. infection, we think, there is evi-
dence to recommend the use of this probiotic formula
along with standard triple therapy as an option for de-
creasing overall therapy related side effects and slightly
increasing the eradication rates.
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